Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries

Catalin O Codreanu,1 Nemanja Damjanov2 1Rheumatology Department, Center of Rheumatic Diseases, Bucharest, Romania; 2Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, SerbiaAbstract: Over the past decade, the use of biologics has significantly changed the management of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Codreanu C, Damjanov N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/748d502621814fdc9fac5569ae97662a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:748d502621814fdc9fac5569ae97662a
record_format	dspace
spelling	oai:doaj.org-article:748d502621814fdc9fac5569ae97662a2021-12-02T04:40:29ZSafety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries1177-5491https://doaj.org/article/748d502621814fdc9fac5569ae97662a2015-01-01T00:00:00Zhttp://www.dovepress.com/safety-of-biologics-in-rheumatoid-arthritis-data-from-randomized-contr-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Catalin O Codreanu,1 Nemanja Damjanov2 1Rheumatology Department, Center of Rheumatic Diseases, Bucharest, Romania; 2Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, SerbiaAbstract: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA). Biologics selectively target components of the immune system, resulting in better disease control. However, the growing use of biologics in RA has increased safety concerns among rheumatologists. Randomized controlled trials (RCTs) and registries are the most reliable sources of clinical safety data. Although safety data from RCTs provide certain insights into the clinical safety profile of an agent, strict constraints in study design (eg, exclusion criteria and restrictive treatment protocols) often do not accurately reflect possible safety issues in the use of the agent, either in the clinical setting or over long-term treatment. Registries, on the other hand, are not restrictive regarding patient enrollment, making them more reliable in evaluating long-term safety. A number of registries have been established globally: in Europe, the United States, and Asia. However, the availability of registry data from Eastern Europe is lacking. The notable exceptions so far are registries from the Czech Republic (ATTRA, a registry of patients treated with anti-tumor necrosis factor-alpha drugs) and Serbia (National registry of patients with rheumatoid arthritis in Serbia [NARRAS]). The current report provides an overview of safety data with biologics in RA from RCTs and registries. Availability of regional safety data from Eastern Europe is of great importance to its clinicians for making evidence-based treatment decisions in RA. Keywords: biologic therapy, biologic drugs, adverse events, infections, pregnancy, malignanciesCodreanu CDamjanov NDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 1-6 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Codreanu C Damjanov N Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
description	Catalin O Codreanu,1 Nemanja Damjanov2 1Rheumatology Department, Center of Rheumatic Diseases, Bucharest, Romania; 2Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, SerbiaAbstract: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA). Biologics selectively target components of the immune system, resulting in better disease control. However, the growing use of biologics in RA has increased safety concerns among rheumatologists. Randomized controlled trials (RCTs) and registries are the most reliable sources of clinical safety data. Although safety data from RCTs provide certain insights into the clinical safety profile of an agent, strict constraints in study design (eg, exclusion criteria and restrictive treatment protocols) often do not accurately reflect possible safety issues in the use of the agent, either in the clinical setting or over long-term treatment. Registries, on the other hand, are not restrictive regarding patient enrollment, making them more reliable in evaluating long-term safety. A number of registries have been established globally: in Europe, the United States, and Asia. However, the availability of registry data from Eastern Europe is lacking. The notable exceptions so far are registries from the Czech Republic (ATTRA, a registry of patients treated with anti-tumor necrosis factor-alpha drugs) and Serbia (National registry of patients with rheumatoid arthritis in Serbia [NARRAS]). The current report provides an overview of safety data with biologics in RA from RCTs and registries. Availability of regional safety data from Eastern Europe is of great importance to its clinicians for making evidence-based treatment decisions in RA. Keywords: biologic therapy, biologic drugs, adverse events, infections, pregnancy, malignancies
format	article
author	Codreanu C Damjanov N
author_facet	Codreanu C Damjanov N
author_sort	Codreanu C
title	Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
title_short	Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
title_full	Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
title_fullStr	Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
title_full_unstemmed	Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
title_sort	safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/748d502621814fdc9fac5569ae97662a
work_keys_str_mv	AT codreanuc safetyofbiologicsinrheumatoidarthritisdatafromrandomizedcontrolledtrialsandregistries AT damjanovn safetyofbiologicsinrheumatoidarthritisdatafromrandomizedcontrolledtrialsandregistries
_version_	1718401127071875072

Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries

Ejemplares similares